Onkologie 2020: 14(Suppl.F): 154-155 | DOI: 10.36290/xon.2020.086

First-line pembrolizumab for metastatic non-small-cell lung cancer

Markéta Černovská, Marie Drösslerová
Pneumologická klinika Thomayerovy nemocnice a 1. LF UK, Praha

Immunotherapy is a form of cancer treatment that uses the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. Immunotherapy do not target the tumor directly but they interfere with the ability of cancer cells to avoid immune system attack. Antibodies against the PDL-1 receptor and its PDL-1 ligand are the main focus of recent studies. Pembrolizumab is a humanized monoclonal immunoglobulin antibody directed against human cell surface receptor PD-1 (programmed cell death-1).

Keywords: immunotherapy, immunosenescence, lung cancer, monoclonal antibody, pembrolizumab.

Published: November 19, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Černovská M, Drösslerová M. First-line pembrolizumab for metastatic non-small-cell lung cancer. Onkologie. 2020;14(Suppl.F / Onkologické kazuistiky 5):154-155. doi: 10.36290/xon.2020.086.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016; 375: 1823-1833. Go to original source... Go to PubMed...
    2. Reck M, Rodríguez-Abreu D, Robinson AG, Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50 % or Greater, J Clin. Oncol. 2019 Mar 1; 37(7): 537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.J Clin Oncol. 2019. PMID: 30620668 Clinical Trial. Go to original source... Go to PubMed...
    3. Keytruda, SPC,https://ec.europa.eu/health/documents/community-register/2017/20171208139385/anx_139385_cs.pdf.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.